C
CardioSignal
Health Tech & Medtech · Turku, Finland · Founded 2016
Smartphone application for early heart disease detection MoreLess
CardioSignal, a brand of the Finnish health technology company Precordior, develops digital cardiac biomarkers for the early detection of heart disease. Founded in 2015 as an academic spinoff from the University of Turku, the company is headquartered in Turku, Finland, with a presence in Palo Alto, California. The co-founder and CEO is Dr. Juuso Blomster, a cardiologist and Adjunct Professor of Cardiology at the University of Turku. His background includes various international roles in the medical and pharmaceutical industries.
The company's core technology, gyrocardiography, utilizes the built-in gyroscope and accelerometer in smartphones to non-invasively measure chest micro-vibrations caused by heart motion. This patented method is the result of over a decade of academic research and algorithm development. The CardioSignal mobile application is a CE-marked Class IIb medical device that can detect signs of atrial fibrillation in one minute with 96% accuracy. The technology is also being validated for other cardiovascular conditions, including heart failure, aortic stenosis, and coronary artery disease.
CardioSignal operates on a software-as-a-medical-device (SaMD) business model. It serves individual users for self-monitoring, healthcare providers for remote care and point-of-care diagnostics, and organizations for population health initiatives. The company generates revenue through its mobile application and is also developing a 'CardioSignal Inside' SDK for integration into other mobile health apps. As of January 2024, CardioSignal has raised a total of $23 million in funding over three rounds, with its latest Series A round raising $10 million, led by DigiTx Partners. The company has established partnerships with entities like Novartis and JISEKI Health and is working with the FDA for market entry into the United States.
Keywords: gyrocardiography, digital cardiac biomarker, heart disease detection, atrial fibrillation, mobile health, remote patient monitoring, medical device software, cardiovascular diagnostics, smartphone sensor, health technology, preventative care, point-of-care, cardiac monitoring, CE mark, Class IIb medical device, heart failure detection, clinical validation, academic spinoff, digital health, non-invasive diagnostics
Company overview
CardioSignal company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Turku, Finland
- Employees
- 33
- Open positions
- None listed
- Dealroom signal
- 77.9
Valuation & funding
CardioSignal funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2024 | $10M | $40M | Maki.vc · DigiTx Partners · Sandwater | ↗ |
| SEEDEquity / VC | Sep 2021 | $2.4M | $9.7M | Maki.vc | — |
| SEEDEquity / VC | Jan 2021 | $2.4M | $9.7M | Undisclosed | — |
| GRANT✓Other financing | Jan 2020 | $2M | — | European Innovation Council | — |
| SPINOUT✓Other financing | Dec 2016 | $0 | — | University of Turku | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
CardioSignal website traffic
Latest recorded traffic for CardioSignal is 3.4K monthly website visits, down 19% over the last three months. CardioSignal's team grew 0% over the past year.
Comparisons
CardioSignal compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
CardioSignal's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where CardioSignal has talent and traffic
team presence
In the news
Latest news about CardioSignal
Recent press, funding announcements, and product moves mentioning CardioSignal — open to read from the original sources.
Market sentiment
What the market is saying about CardioSignal
An AI-synthesized read of the highest-engagement posts about CardioSignal on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CardioSignal’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.